High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer

Esther Reijm, Mieke Timmermans, Maxime Look, Marion Gelder, CK Stobbe, Carolien van Deurzen, John Martens, Stefan Sleijfer, John Foekens, Els Berns, Maurice Jansen

Research output: Contribution to journalArticleAcademicpeer-review

48 Citations (Scopus)


In MBC, increased mRNA levels of Enhancer of Zeste Homolog 2 (EZH2) have been shown to be associated with worse outcome to tamoxifen therapy. We confirm this association on protein expression level in an independent cohort of patients. This suggests that EZH2 protein expression can be used as a marker to predict outcome to tamoxifen therapy which provides more support to explore EZH2 inhibition in the clinical setting to come to a more personalized treatment approach.Metastatic breast cancer (MBC) is a highly heterogeneous disease with great differences in outcome to both chemo- and endocrine therapy. Better insight into the mechanisms underlying resistance is essential to better predict outcome to therapy and to obtain a more tailored treatment approach. We have previously described that increased mRNA expression levels of Enhancer of Zeste homolog (EZH2) are associated with worse outcome to tamoxifen therapy in MBC. Here, we explored whether this is also the case for EZH2 protein expression. A tissue microarray (TMA) was created using formalin-fixed, paraffin-embedded estrogen receptor (ER)-positive primary breast tumor tissues of 250 MBC patients treated with first-line tamoxifen. Quantity and intensity of EZH2 expression were determined by immunohistochemistry (IHC) and both were used to generate and group scores according to a previously described method for scoring EZH2. In total, 116 tumors (46%) were considered to be EZH2 positive. The presence of EZH2 protein expression was significantly associated with progression-free survival (PFS) in both univariate [hazard ratio (HR) 1.51, 95% confidence interval (CI) 1.17-1.97, P = 0.002] and multivariate analysis including traditional factors associated with tamoxifen outcome (HR 1.41, 95% CI 1.06-1.88, P = 0.017). Considering quantity irrespective of intensity, tumors with > 50% EZH2-positive cells had the worst PFS (HR 2.15, 95% CI 1.42-3.27, P < 0.001), whereas intensity alone did not show a significant association with PFS. Application of other methods of scoring EZH2 positivity resulted in a similar significant association between the amount of EZH2 positive cells and PFS. In addition to EZH2 mRNA levels, these results suggest that protein expression of EZH2 can be used as a marker to predict outcome to tamoxifen therapy. This provides new rationale to explore EZH2 inhibition in the clinical setting and increases the possibilities for a more personalized treatment approach in MBC patients.
Original languageUndefined/Unknown
Pages (from-to)2185-2190
Number of pages6
JournalAnnals of Oncology
Issue number11
Publication statusPublished - 2014

Cite this